Ghent University Academic Bibliography

Advanced

Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes: a post-marketing surveillance study

Lucas Van Bortel (2010) EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES. 14(9). p.749-758
abstract
Background and Objectives: Hypertension is a widely prevalent condition of elevated blood pressure (BP) and is the leading risk factor for the development of cardiovascular disease (CVD). Many patients have additional risk factors such as diabetes mellitus (DM) or previous history of CVD. Nebivolol is a third-generation beta (beta)-blockers which has been shown not to influence metabolic parameters in patients with DM. This post-marketing surveillance study aimed to collect information on the efficacy, safety and tolerability of nebivolol in hypertensive patients with concomitant DM. Patients and Methods: Hypertensive patients with DM followed by 52 cardiologists, internal medicine specialists and general practitioners, between :24 August 2003 and 9 January 2007 in the Netherlands were included in this study. Physicians were asked to survey nebivolol treatment for 6 months. Results: A total of 510 patients were enrolled. Overall, 93.3% of patients were diagnosed with essential hypertension and 6.7% with secondary hypertension. All patients were co-diagnosed with DM. Nebivolol therapy was associated with a significant reduction in both systolic blood pressure (BP) and diastolic BP versus baseline (p<0.001 for both). These reductions were seen regardless of reason for initiation of nebivolol (i.e. first diagnosis of hypertension, resistance or intolerance to previous antihypertensive medication, or other reasons). A significant improvement in blood glucose was seen at 4 months (-0.6 mmol/L; p=0.021). Significant reductions in total cholesterol (-1.45 mmol/L; p=0.006), low density lipoprotein (LDL) cholesterol (-1.32 mmol/L; p=0.003) and LDL/high density lipoprotein (HDL) cholesterol ratio (-0.77; p=0.011) were observed at 2 months. No significant changes were seen in HDL cholesterol and triglycerides. Conclusion: Nebivolol treatment was associated with a significantly reduced BP, improved blood glucose and LDL cholesterol levels and was well tolerated in hypertensive patients with concomitant DM.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
Glycaemic profile, Diabetes, Hypertension, Nebivolol, Lipidic profile, ARTERIAL-HYPERTENSION, BETA-BLOCKERS, ANTIHYPERTENSIVE THERAPY, EUROPEAN-SOCIETY, GLYCEMIC CONTROL, BLOOD-PRESSURE, MANAGEMENT, GUIDELINES, MELLITUS, ATENOLOL
journal title
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
Eur. Rev. Med. Pharmacol. Sci.
volume
14
issue
9
pages
749 - 758
Web of Science type
Article
Web of Science id
000282540900003
JCR category
PHARMACOLOGY & PHARMACY
JCR impact factor
0.922 (2010)
JCR rank
202/249 (2010)
JCR quartile
4 (2010)
ISSN
1128-3602
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1167051
handle
http://hdl.handle.net/1854/LU-1167051
date created
2011-02-23 14:23:50
date last changed
2016-12-19 15:46:40
@article{1167051,
  abstract     = {Background and Objectives: Hypertension is a widely prevalent condition of elevated blood pressure (BP) and is the leading risk factor for the development of cardiovascular disease (CVD). Many patients have additional risk factors such as diabetes mellitus (DM) or previous history of CVD. Nebivolol is a third-generation beta (beta)-blockers which has been shown not to influence metabolic parameters in patients with DM. This post-marketing surveillance study aimed to collect information on the efficacy, safety and tolerability of nebivolol in hypertensive patients with concomitant DM.
Patients and Methods: Hypertensive patients with DM followed by 52 cardiologists, internal medicine specialists and general practitioners, between :24 August 2003 and 9 January 2007 in the Netherlands were included in this study. Physicians were asked to survey nebivolol treatment for 6 months.
Results: A total of 510 patients were enrolled. Overall, 93.3\% of patients were diagnosed with essential hypertension and 6.7\% with secondary hypertension. All patients were co-diagnosed with DM. Nebivolol therapy was associated with a significant reduction in both systolic blood pressure (BP) and diastolic BP versus baseline (p{\textlangle}0.001 for both). These reductions were seen regardless of reason for initiation of nebivolol (i.e. first diagnosis of hypertension, resistance or intolerance to previous antihypertensive medication, or other reasons). A significant improvement in blood glucose was seen at 4 months (-0.6 mmol/L; p=0.021). Significant reductions in total cholesterol (-1.45 mmol/L; p=0.006), low density lipoprotein (LDL) cholesterol (-1.32 mmol/L; p=0.003) and LDL/high density lipoprotein (HDL) cholesterol ratio (-0.77; p=0.011) were observed at 2 months. No significant changes were seen in HDL cholesterol and triglycerides.
Conclusion: Nebivolol treatment was associated with a significantly reduced BP, improved blood glucose and LDL cholesterol levels and was well tolerated in hypertensive patients with concomitant DM.},
  author       = {Van Bortel, Lucas},
  issn         = {1128-3602},
  journal      = {EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES},
  keyword      = {Glycaemic profile,Diabetes,Hypertension,Nebivolol,Lipidic profile,ARTERIAL-HYPERTENSION,BETA-BLOCKERS,ANTIHYPERTENSIVE THERAPY,EUROPEAN-SOCIETY,GLYCEMIC CONTROL,BLOOD-PRESSURE,MANAGEMENT,GUIDELINES,MELLITUS,ATENOLOL},
  language     = {eng},
  number       = {9},
  pages        = {749--758},
  title        = {Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes: a post-marketing surveillance study},
  volume       = {14},
  year         = {2010},
}

Chicago
Van Bortel, Lucas. 2010. “Efficacy, Tolerability and Safety of Nebivolol in Patients with Hypertension and Diabetes: a Post-marketing Surveillance Study.” European Review for Medical and Pharmacological Sciences 14 (9): 749–758.
APA
Van Bortel, L. (2010). Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes: a post-marketing surveillance study. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 14(9), 749–758.
Vancouver
1.
Van Bortel L. Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes: a post-marketing surveillance study. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES. 2010;14(9):749–58.
MLA
Van Bortel, Lucas. “Efficacy, Tolerability and Safety of Nebivolol in Patients with Hypertension and Diabetes: a Post-marketing Surveillance Study.” EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 14.9 (2010): 749–758. Print.